Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia ; volume:78 ; number:18 ; day:12 ; month:12 ; year:2018 ; pages:1911 ; date:12.2018
Drugs ; 78, Heft 18 (12.12.2018), 1911, 12.2018
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-018-1034-z
- URN
-
urn:nbn:de:101:1-2019013120283425921059
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Single cell analysis of clonal architecture in acute myeloid leukaemia
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Single cell analysis of clonal architecture in acute myeloid leukaemia
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Identification of CDX2 targets in acute myeloid leukaemia
Decreased MMP1 gene expression in acute myeloid leukaemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia